Medicare Part D prescription drug plans may cover Zepbound when a doctor prescribes it for OSA. However, Medicare will not cover Zepbound and other anti-obesity medications (AOMs) for weight ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

The Centers for Medicare & Medicaid Services on Friday rejected a Biden administration proposal to expand Medicare coverage of weight-loss drugs such as Eli Lilly's Zepbound and Novo Nordisk's ...

It is not approved solely for obesity, however, and Medicare does not cover it for that purpose. Zepbound, a second form of tirzepitide produced by Eli Lilly, is FDA approved for chronic weight ...

Advertisement Advertisement The Biden proposal would have included coverage of Wegovy and Zepbound to treat obesity under Medicare Part D for Medicare Advantage. “While today’s announcement ...

The Trump administration says it will not move forward with a Biden proposal that Medicare cover anti-obesity drugs such as Novo Nordisk’s Wegovy and Zepbound from Eli Lilly. The drugs have been ...

Due to current legislation regarding weight loss drugs, Medicare Part D or Part C plans with drug coverage may only cover Zepbound for treating obstructive sleep apnea (OSA). However, the Centers ...